Name
GS3-10 - Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDKz, in combination with fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer
Date & Time
Tuesday, December 7, 2021
Speakers
Virtual Session Link